newsfilter
← Latest News
PR Newswire·

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

SAN DIEGO, Nov. 7, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the